Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: Systems and methods for presenting a sequence of medical images are provided herein. A use provides an input which indicates that additional frames are to be displayed. Frames from the sequence are displayed in succession, without skipping the display of any frames, based on a frame rate determined by an input provided by a user.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: In a system for determining a location of an emitter, a mobile frame is configured for movement relative to the emitter. A main receiver and a frequency mixing antenna are supported on the mobile frame at different locations on the frame but so that both move with the frame relative to the emitter. The frequency mixing antenna is configured to receive an emitter signal and output a frequency-mixed signal. The main receiver is configured to directly receive the emitter signal and receive the frequency-mixed signal. A processor is configured to determine a first Doppler frequency from the direct emitter signal and a second Doppler frequency from the frequency-mixed signal and to determine the location of the emitter in a defined search area based on the first and second Doppler frequencies. Multiple Doppler frequencies can be created also using multiple frequency mixing antennas to improve the localization resolution.

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: Systems and methods for presenting a sequence of medical images are provided herein. A use provides an input which indicates that additional frames are to be displayed. Frames from the sequence are displayed in succession, without skipping the display of any frames, based on a frame rate determined by an input provided by a user.

Abstract: Methods for treating fibrodysplasia ossificans progressiva (FOP) in human subjects are provided. Such methods involve administering to a subject having FOP a therapeutically effective amount of an Activin A antagonist, such as an antibody against Activin A.

Abstract: The present invention provides dosing regimens of anti-C5 antibodies, such as pozelimab, for treating or preventing C5-associated diseases such as paroxysmal nocturnal hemoglobinuria or CHAPLE disease.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ?1 point reduction or a ?2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. Also provided are methods of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ?1 point reduction or a ?2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration.

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

Abstract: A coupler or connector for joining bars, for example reinforcing bars, including an elongate rod member adapted to be inserted into a tubular sleeve member. The rod and sleeve members each have one or more transverse holes which align when the rod member is inserted into the sleeve member. In operational use, the rod and sleeve members are attached to the free ends of the bars to be connected. One or more transverse pins are then driven into the holes which are aligned in order to lock the rod and sleeve member together thereby connecting the bars. The pins can be spring loaded. There can be a plastic sleeve adapted to retain the pins in position. The plastic sleeve is slid off during assembly to allow the pins to engage the holes in the sleeve member(s).

Abstract: A lifting device for brittle elements such as bridge beam and deck elements, panels and the like up to and beyond 1,000 tonnes is described. The lifting device may be suitable for face and edge lifting of brittle elements that have a suitable cavity formed within or through them. The lifting device may include a lifting eye connected to an elongate member/shank that has a flared end. A sleeve about the shank may be used to raise and lower the moveably attached wedges to and from the flared end. In use the wedges upon the flared end prevent the withdrawal of the lifting device from the cavity of the brittle element. A cavity former is also described that may be used in the casting of the brittle element to form a suitable cavity.

Abstract: A lifting device (110) for concrete elements such as bridge beam and deck elements, panels and the like up to and beyond 1,000 tons (t) is described. The lifting device may be suitable for face and edge lifting of concrete elements that have a suitable cavity formed within or through them. The lifting device (110) may include a lifting eye (116) connected to an elongate member/shank (114) that has a flared end (122). A sleeve (126) about the shank (114) may be used to raise and lower the moveably attached wedges (124) to and from the flared end (122). In use the wedges (124) upon the flared end (122) prevent the withdrawal of the lifting device (110) from the cavity of the concrete element. A cavity former is also described that may be used in the casting of the concrete element to form a suitable cavity.